List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. Europe Monoclonal Antibodies Market, 2019-2030, $ bn 19
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Europe Monoclonal Antibodies Market 25
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 9. Primary Restraints and Impact Factors of Europe Monoclonal Antibodies Market 30
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of Europe Monoclonal Antibodies Market 37
Figure 12. Breakdown of Europe Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue 42
Figure 13. Europe Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%) 42
Figure 14. Europe Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn 43
Figure 15. Europe Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn 44
Figure 16. Europe Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn 45
Figure 17. Europe Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn 46
Figure 18. Breakdown of Europe Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue 48
Figure 19. Europe Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%) 48
Figure 20. Europe Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn 49
Figure 21. Europe Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn 50
Figure 22. Breakdown of Europe Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue 52
Figure 23. Europe Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%) 52
Figure 24. Europe Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn 53
Figure 25. Europe Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn 54
Figure 26. Breakdown of Europe Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue 56
Figure 27. Europe Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%) 56
Figure 28. Europe Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn 57
Figure 29. Europe Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn 59
Figure 30. Europe Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn 60
Figure 31. Europe Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn 61
Figure 32. Europe Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn 62
Figure 33. Europe Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn 63
Figure 34. Europe Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn 64
Figure 35. Europe Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn 65
Figure 36. Europe Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn 66
Figure 37. Europe Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn 67
Figure 38. Breakdown of Europe Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue 69
Figure 39. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%) 69
Figure 40. Europe Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn 70
Figure 41. Europe Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn 71
Figure 42. Europe Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn 72
Figure 43. Breakdown of European Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 74
Figure 44. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 75
Figure 45. Monoclonal Antibodies Market in Germany, 2019-2030, $ bn 76
Figure 46. Monoclonal Antibodies Market in U.K., 2019-2030, $ bn 78
Figure 47. Monoclonal Antibodies Market in France, 2019-2030, $ bn 80
Figure 48. Monoclonal Antibodies Market in Spain, 2019-2030, $ bn 82
Figure 49. Monoclonal Antibodies Market in Italy, 2019-2030, $ bn 84
Figure 50. Monoclonal Antibodies Market in Russia, 2019-2030, $ bn 86
Figure 51. Monoclonal Antibodies Market in Rest of Europe, 2019-2030, $ bn 88
Figure 52. Growth Stage of Europe Monoclonal Antibodies Industry over the Forecast Period 90
Europe monoclonal antibodies market was valued at $40.8 billion in 2020 and will grow by 11.0% annually over 2020-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies. Highlighted with 34 tables and 52 figures, this 110-page report “Europe Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country. Based on Source, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Human • Humanized • Chimeric • Murine Based on Category, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Branded mAbs • Biosimilar mAbs Based on Production Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • In Vitro Production • In Vivo Production Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Cancer • Breast Cancer • Colorectal Cancer • Lung Cancer • Ovarian Cancer • Other Cancer Types • Autoimmune Diseases • Inflammatory Diseases • Infectious Diseases • Other Applications By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospitals • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories AbbVie, Inc. Amgen Inc. AstraZeneca plc Bayer AG Bristol-Myers Squibb Company Eli Lilly F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson & Johnson Merck & Co., Inc. Mylan N.V Norvatis AG Pfizer Sanofi S.A. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More